Stem Cell Clinic

Researchers Recreate Pain-Sensing Neurons

By Stem Cell Medical Center

Researchers at the Harvard Stem Cell Institute and the Stem Cell and Regenerative Biology Department have successfully developed pain-sensing neurons from mouse and human skin cells, according to a report published in Nature Neuroscience in late November.

The study specifically aimed to simulate primary afferent nociceptors, very specialized pain-sensing neurons.

According to head researcher Clifford J. Woolf, a professor of Neurology and Neurobiology at theMedical School, the findings may lead to development of more effective pain medications, better methods to evaluate who is at risk for developing chronic pain, and ways to combat pain complications resulting from cancer chemotherapy.

What weve been able to do with stem cell technology for the first time is recreate some of the key elements of the nervous system by taking one cell and turning it into a particular other cell, Woolf said. This enables us for the first time to really dissect how human neurons function in the nervous system.

For Woolf, the study is a culmination of many years of research, previously done only in mouse cells.

The fact that we can even create these cells with a human gives us the opportunity to study the mechanisms of the way human nervous systems work that havent been possible before, Woolf said.

Tony L. Yaksh, co-director of the Pain and Symptom Management Core of the University of California at San Diegos Regional Cancer Center, emphasized the studys role in raising new questions for further research.

I think this is highly innovative and an extremely well-done paper, Yaksh said. Id say this represents a very concerted, well-organized group effort to define this very critical issue. It leaves you with more questions than before you read the paper, but it starts the ball rolling in a very exciting way.

Yaksh also highlighted the importance of the study in streamlining gene-specific treatment.

The significance is [that] this allows us to define a mechanism that may be relevant to pain transmission in humans without having to euthanize a human being, Yaksh said.

Read the original:
Researchers Recreate Pain-Sensing Neurons

Fear of unknown barrier to iPS cures, expert says

By Stem Cell Medical Center

Masayo Takahashi, who led the worlds first operation to implant induced pluripotent stem (iPS) cells into a human body, says greater Japanese understanding of the risks and benefits of new medical procedures is key to achieving her goal of standardizing the procedure one day.

About two months after her team successfully transplanted retinal cells grown from iPS cells into a woman in her 70s with age-related macular degeneration, Takahashi, an ophthalmologist at the Riken Center for Developmental Biology in Kobe, said she wanted to make the treatment available and affordable in about 10 years.

My goal is to make the treatment a standard one, Takahashi said Wednesday at the Foreign Correspondents Club of Japan in Tokyo, adding that the pioneering operation in September was just a start.

The operation was primarily aimed at checking for any medical problems that might arise, including the possibility of cancer, after iPS-derived retinal cells were transplanted to the patient, whose form of the disease could lead to loss of vision.

It is expected to take around a year to assess the safety and side effects of the transplant operation.

The most difficult part of the surgery was removal of damaged tissue, Takahashi said. So we were very excited when the damaged tissue was removed safely.

The surgery, performed by a team of researchers at the Riken institute and the Institute of Biomedical Research and Innovation Hospital, was the first in which iPS-derived cells were introduced into a human body.

Developed by Nobel Prize-winning Kyoto University professor Shinya Yamanaka, iPS cells are a versatile type of stem cell that can grow into various types of human body tissue.

However, a potential obstacle to spreading the treatment is reluctance among Japanese to take risks when they encounter something new, including medical treatments, according to Takahashi.

In Japan, people dont accept risks at all, she said, adding it is necessary to accept a certain level of risk when receiving advanced medicine and it is important to understand the balance between risks and benefits.

The rest is here:
Fear of unknown barrier to iPS cures, expert says

Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and …

By Uncategorized

MIAMI (PRWEB) December 01, 2014

MIAMI, Dec. 1, 2014Stem Cell Training, Inc., a division of Global Stem Cells Group, Inc., has announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2015.

The program will include five days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Global Stem Cells Group Advisory Board member Dr. David B. Harrell, PhD will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.

Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and FDA registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting

The graduate course is to be held four times in Miami in 2015.

Course details, objectives and instruction include:

Didactic Lectures will include:

For additional information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Read the original here:
Global Stem Cell Groups Stem Cell Training to Launch Post-graduate Studies Program in Stem Cell Therapies and ...

Kidney organ regeneration research leaps forward

By Uncategorized

Okayama City, Japan (PRWEB UK) 2 December 2014

Researchers at Okayama University Graduate School of Medicine and Kyorin University School of Medicine have successfully generated a kidney-like structure from just a single cell.

It has been predicted that the kidney will be among the last organs successfully regenerated in vitro due to its complex structure and multiple functions, states Shinji Kitamura, Hiroyuki Sakurai and Hirofumi Makino at the beginning of their latest report, before continuing to describe results suggesting a far more positive prognosis for the pace of kidney regeneration research. Despite the anatomical challenges posed by the kidney anatomy and the complexities understood from embryonic kidney development processes, the researchers have demonstrated that kidney-like structures can be generated from just a single adult kidney stem cell.

In embryos, kidney development requires two types of primordial cells cells at the earliest stage of development. However by generating kidney-like structures from a single type of kidney stem cell the researchers provide evidence for differences in the organ development in adults and embryos.

Kitamura, Sakurai and Makino researchers from Okayama and Kyorin Universities - took kidney stem cells from the different kidney components of microdissected adult rats and grew them in culture. A method for growing three-dimensional cell clusters showed that kidney-like structures could form so long as the initial cell cluster was large enough.

The minimum cluster size required might suggest that not all the kidney stem cells have stem cell characteristics. Therefore the researchers cloned kidney stem cells and confirmed that kidney-like structures still formed from the clusters of clone cells after a few weeks.

The researchers add, Although the physiological roles of such cells are currently unclear, analogous cells in the adult human kidney would be a valuable resource for the regeneration of kidneys in vitro.

Background Kidney structure There are more than a dozen distinct types of cell in the kidneys. The basic structural unit of the kidney is the nephron, which filters the blood to regulate the concentration of water and soluble substances such as sodium salts. Each nephron comprises several well-defined segments: the glomerulus, the proximal tubule, the loop of Henle, the distal tube and the collecting duct.

In embryo kidney organogenesis two primordial cell types are required to differentiate into all the different cell types in the kidney: metanephric mesenchymal cells and uteric bud cells. Kitamura, Sakurai and Makino produced kidney cells that could differentiate into a kidney-like structure without these primordial cell types, suggesting these are adult kidney stem cells.

Obtaining kidney stem cells The researchers microdissected adult rat kidneys into segments from the glomeruli, proximal convoluted tubule (S1/PCT), proximal straight tubule (S2, S3), medullary thick ascending limb of Henles loop and the collecting duct. They then grew the cells on mouse mesenchymal cells. While there is no known single biomarker for adult kidney stem cells, immunohistochemical anaylysis identified a number of markers in the kidney stem cells- that are found in embryonic or adult kidneys.

See more here:
Kidney organ regeneration research leaps forward

Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

By Uncategorized

MIAMI (PRWEB) December 01, 2014

GlobalStemCellsGroup.com has announced plans to team with Portal Medestetica, the largest physician portal in Lain America, to launch Portalstemcells.com, a new portal dedicated to providing physicians in Spain and Latin America with relevant information, clinical research news and products relating to stem cells and regenerative medicine.

The new collaboration between Global Stem Cells Group and Portal Medestetica will answer a growing need to expand the reach of high-impact news, studies and breakthroughs, and significantly advance the clinical utilization of stem cell research and clinical trials throughout Latin America. The Portalstemcells.com site is designed to help promote the latest state-of-the-art developments in regenerative medicine as they become available, and to share educational content with physicians throughout the region.

Portalstemcells.com will be the ideal vehicle to promote education and cutting-edge science throughout the region, says Ricardo de Cubas, founder of Global Stem Cells Group. The potential of regenerative medicine and stem cells therapies inspiring the medical community to find real opportunities to repair or replace tissue damaged from disease, relieve pain and provide the potential for curing chronic diseases where no cure existed before.

The Portalstemcells.com site is aimed at fostering growth and ethical development in the fast-moving field of stem cell medicine by filling a gap in the resources available throughout Latin America. The goal is to elevate the delivery of stem cell science in order to impact the lives of many patients worldwide.

For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

See more here:
Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

Cardiac Stem Cells (CSCs) | University of Maryland Medical …

By Stem Cell Medical Center

For immediate release: September 10, 2012

Baltimore, MD --Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the regenerative abilities of neonatal and adult-derived human cardiac stem cells. Among their findings: cardiac stem cells (CSCs) from newborns have a three-fold ability to restore heart function to nearly normal levels compared with adult CSCs. Further, in animal models of heart attack, hearts treated with neonatal stem cells pumped stronger than those given adult cells. The study is published in the September 11, 2012, issue of Circulation.

The surprising finding is that the cells from neonates are extremely regenerative and perform better than adult stem cells, says the study's senor author, Sunjay Kaushal, M.D., Ph.D., associate professor of surgery at the University of Maryland School of Medicine and director, pediatric cardiac surgery at the University of Maryland Medical Center. We are extremely excited and hopeful that this new cell-based therapy can play an important role in the treatment of children with congenital heart disease, many of whom don't have other options.

Dr. Kaushal envisions cellular therapy as either a stand-alone therapy for children with heart failure or an adjunct to medical and surgical treatments. While surgery can provide structural relief for some patients with congenital heart disease and medicine can boost heart function up to two percent, he says cellular therapy may improve heart function even more dramatically. We're looking at this type of therapy to improve heart function in children by 10, 12, or 15 percent. This will be a quantum leap in heart function improvement.

Heart failure in children, as in adults, has been on the rise in the past decade and the prognosis for patients hospitalized with heart failure remains poor. In contrast to adults, Dr. Kaushal says heart failure in children is typically the result of a constellation of problems: reduced cardiac blood flow; weakening and enlargement of the heart; and various congenital malformations. Recent research has shown that several types of cardiac stem cells can help the heart repair itself, essentially reversing the theory that a broken heart cannot be mended.

Stem cells are unspecialized cells that can become tissue- or organ-specific cells with a particular function. In a process called differentiation, cardiac stem cells may develop into rhythmically contracting muscle cells, smooth muscle cells or endothelial cells. Stem cells in the heart may also secrete growth factors conducive to forming heart muscle and keeping the muscle from dying.

To conduct the study, researchers obtained a small amount of heart tissue during normal cardiac surgery from 43 neonates and 13 adults. The cells were expanded in a growth medium yielding millions of cells. The researchers developed a consistent way to isolate and grow neonatal stem cells from as little as 20 milligrams of heart tissue. Adult and neonate stem cell activity was observed both in the laboratory and in animal models. In addition, the animal models were compared to controls that were not given the stem cells.

Dr. Kaushal says it is not clear why the neonatal stem cells performed so well. One explanation hinges on sheer numbers: there are many more stem cells in a baby's heart than in the adult heart. Another explanation: neonate-derived cells release more growth factors that trigger blood vessel development and/or preservation than adult cells.

This research provides an important link in our quest to understand how stem cells function and how they can best be applied to cure disease and correct medical deficiencies, says E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs, University of Maryland; the John Z. and Akiko K. Bowers Distinguished Professor; and dean, University of Maryland School of Medicine. Sometimes simple science is the best science. In this case, a basic, comparative study has revealed in stark terms the powerful regenerative qualities of neonatal cardiac stem cells, heretofore unknown.

Insights gained through this research may provide new treatment options for a life-threatening congenital heart syndrome called hypoplastic left heart syndrome (HLHS). Dr. Kaushal and his team will soon begin the first clinical trial in the United States to determine whether the damage to hearts of babies with HLHS can be reversed with stem cell therapy. HLHS limits the heart's ability to pump blood from the left side of the heart to the body. Current treatment options include either a heart transplant or a series of reconstructive surgical procedures. Nevertheless, only 50-60 percent of children who have had those procedures survive to age five.

See the rest here:
Cardiac Stem Cells (CSCs) | University of Maryland Medical ...

Newport Beach Stem Cell Treatment Center – Stem Cell …

By Stem Cell Clinic

The Newport Beach Stem Cell Treatment Center provides cutting-edge care for patients with a wide variety of degenerative disorders using adult stem cell regenerative therapy. Our highly trained physicians and medical team are focused on providing you with the most innovative techniques and advanced procedures for harvesting and deploying adult stem cells from your own fat. We are also committed to clinical research and the advancement of regenerative medicine.

We are dedicated to the principles of personalized patient care and individualized attention. Our plastic surgeon, a pioneer in liposuction, and topnotch team of registered nurses and technicians are experienced in harvesting and deploying adult stem stems. In addition, our comfortable in-office surgery center is fully accredited by the Institute for Medical Quality, a division of the California Medical Association. Our goal is to provide you with the best possible care in a friendly and professional atmosphere.

Fat is the bodys most abundant repository of adult stem cells, containing thousands of times more stem cells than bone marrow. New technologies at the Newport Beach Stem Cell Treatment Center make it possible for us to remove a few ounces of a patients fat through liposuction, separate out the stem cells in a special process that yields extremely high numbers of viable cells, and return them back into the patients body via IV or injection. Performed in a physicians office under sedation and local anesthesia and using a sterile closed system technology (so the cells never come into contact with the environment), there is minimal discomfort and risk of infection. And because the cells come from the patients own body, there is no risk of rejection or disease transmission.

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

Posted by Mark Baldwin on Nov 28, 2012 in Cardiac / Pulmonary

See more here:
Newport Beach Stem Cell Treatment Center - Stem Cell ...

Advances reshape stem cell research

By Stem Cell Treatment

A decade ago, a dream team of researchers from Pittsburgh to South Korea claimed a medical invention that promised to reshape a culture war.

The scientists said they custom-designed stem cells from cloned human embryos. The scientific breakthrough was celebrated around the globe.

Then the bottom fell out.

A scandal erupted over fabricated data, and University of Pittsburgh biologist Gerald Schatten was forced to pull back the findings. Critics cast the 2004 discovery as a farce, a high-profile fraud that forced the journal Science into a rare retraction in January 2006.

Eight years later, the push to use stem cells as a medical treatment continues, but scholars balk at the suggestion that anyone is trying to make genetically identical individuals.

We're not here to clone human beings, for gosh sakes, said John Gearhart, a stem cell researcher and University of Pennsylvania professor in regenerative medicine. Instead, he said, scholars are working to manipulate stem cells to produce heart cells for cardiac patients, brain cells for neurological patients and other custom transplants that could match a person's genetic makeup.

Schatten's work continues at the Magee-Womens Research Institute at Pitt, where university officials cleared him of scientific misconduct, and he remains a vice chairman for research development. He focuses on educating and training physician-scientists and other scientists, a school spokeswoman wrote in a statement. She said Schatten was traveling and was unable to speak with the Tribune-Review.

Researchers have turned the onetime myth of developing stem cells into reality.

At the Oregon Health and Science University, researchers succeeded by blending unfertilized human eggs with body tissue to mold stem cells. Scholars say the cells could let doctors grow customized organs for transplants and other therapies.

The approach engineered by biologist Shoukhrat Mitalipov's research team last year in Portland is among two that scientists are using to forge laboratory-made stem cells the so-called master cells that can transform into other body parts without relying on donated human embryos. Federal law tightly controls the use of taxpayer money for embryonic research.

Link:
Advances reshape stem cell research

Harvard researchers have successfully created human pain in a petri dish

By Stem Cell Doctors

Its not easy to develop new treatments for a disease. In fact, many of the things doctors try never make it past the early stages. This kind of trial and error takes time, but sometimes patients dont have time to wait around for the next big breakthrough. Thats why having a model for safely studying the human body is ideal. You can do a lot of things to a petri dish that you couldnt do to a living, breathing human, and now that petri dish can feel pain. Researchers at the Harvard Stem Cell Institute (HSCI) have created pain sensing neurons outside the human body.

This recently published studyis the culmination of years of intensive research. The project originally began with embryonic stem cells derived from human embryos. These cells are undifferentiated, meaning they have the potential to become any cell type in the body (often called pluripotent). However, the team has issues getting these cells through all the developmental stages to become adult neurons. Just when all seemed lost, there was a breakthrough in stem cell research. A different team developed induced pluripotent stem cells (resulting in a 2012 Nobel Prize), which is just what the HSCI project needed.

An induced pluripotent stem cell begins as a regular skin cell called a fibroblast. By manipulating the cell, researchers can rewind genetic time to make it into a stem cell, then allow it to develop into a completely different cell type. This is how the HSCI team finally found success. Using fibroblasts from mice and humans, the team evaluated all the developmental steps involved to make their pain sensing neurons. The key was the discovery of new transcription factors that cause cells to produce different proteinsessentially flipping on different parts of the genome that make it a neuron.

The neurons created by the HSCI researchers behave just like real human cells that developed the old fashioned way. They can detect the acute pain associated with stubbing your toe or being pricked by a needle, but more importantly, they also pick up on more subtle signals as with chronic pain or inflammation. This is of particular importance in pain disorders because everyone experiences pain differently and theres only so much a physical examination of the nervous system will tell you.

Going with induced pluripotent stem cells wasnt just a way to reach the goal line. This also makes the resulting model more useful. Patients with chronic neuropathic pain donated fibroblastsfor this study, and the neurons created from those cells ended up with the same neuropathies and hypersensitivity seen in the patients own neurons. So not only do you have a piece of the human nervous system in a dish, you have a model of disease in a real person.

Other teams are sure to begin duplicating this research to better understand human disease, and it will be invaluable to analyze pain sensing neurons outside the body. After all, a flesh and blood person will only put up with so much poking and prodding.

Now read:The 3D printed living bandage that could revolutionize skin grafts

Follow this link:
Harvard researchers have successfully created human pain in a petri dish

Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

By Stem Cell Medicine

PUBLIC RELEASE DATE:

26-Nov-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine

Induced pluripotent stem cells made from patients with a form of blistering skin disease can be genetically corrected and used to grow back healthy skin cells in laboratory dishes, researchers at the Stanford University School of Medicine have found. They've termed the new technique "therapeutic reprogramming."

The skin cells formed normal human skin when grafted onto the backs of laboratory mice, they said.

The findings represent a major advance in the battle against the disease, epidermolysis bullosa, in which the top layer of skin, called the epidermis, sloughs off with the slightest friction, leaving open wounds that are difficult to heal. Severely stricken children who survive into their late teens or early 20s often die from invasive squamous cell carcinoma, a skin cancer that can arise during repeated cycles of skin wounding and healing.

"Epidermolysis bullosa is a truly horrible, debilitating skin disease in which the top layer of skin is not properly anchored to the underlying layers," said Anthony Oro, MD, PhD, professor of dermatology. "When they are born, the trauma of birth rips away their skin, and they continue to suffer severe skin wounds that require constant bandaging and medical attention throughout their lives."

Stanford has one of the largest epidermolysis bullosa clinics in the world, with an extremely active and engaged population of patients and their families eager to help researchers. The Stanford Department of Dermatology has been working to find new treatments for the disease for over 20 years. The latest advance, in which researchers replaced the mutated, disease-causing gene in the donor-made induced pluripotent stem cells with a healthy version, was funded by an $11.7 million grant from the California Institute for Regenerative Medicine.

New avenue of treatment

"This treatment approach represents an entirely new paradigm for this disease," Oro said. "Normally, treatment has been confined to surgical approaches to repair damaged skin, or medical approaches to prevent and repair damage. But by replacing the faulty gene with a correct version in stem cells, and then converting those corrected stem cells to keratinocytes, we have the possibility of achieving a permanent fix -- replacing damaged areas with healthy, perfectly matched skin grafts."

Visit link:
Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

→←